Travere Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TVTX)

Historical Holders from Q4 2020 to Q1 2025

Symbol
TVTX on Nasdaq
CUSIP
89422G107
Type / Class
Equity / Common Stock, par value $0.0001 per share
Shares outstanding
76.5M
All holders as of December 31, 2024
Q4 2024
Shares, excl. options
95.1M
Holdings value
$1.66B
% of all portfolios
0.003%
Grand Portfolio weight change
+0%
Number of holders
197
Number of buys
113
Number of sells
-80
Average Value change %
0%
Average buys %
+0.001%
Average sells %
-0.001%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Travere Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TVTX)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ARMISTICE CAPITAL, LLC 9.62% $132M 7.36M Armistice Capital, LLC Dec 31, 2024
VANGUARD GROUP INC 7.75% $121M 6.74M The Vanguard Group Dec 31, 2024
BlackRock, Inc. 7.5% -21.1% $120M -$23.8M 6.69M -16.6% BlackRock, Inc. Mar 31, 2025
Rock Springs Capital Management LP 5.72% $89.1M 4.97M Rock Springs Capital Management LP Dec 31, 2024
MACQUARIE GROUP LTD 4.9% $76.3M 4.26M Macquarie Group Limited Dec 31, 2024
Woodline Partners LP 2.4% $37.9M 2.11M Woodline Partners LP Dec 31, 2024

Institutional Holders of Travere Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TVTX)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q1 551K $9.87M -$1.84M $17.92 12
2024 Q4 95.1M $1.66B +$205M $17.42 197
2024 Q3 82.7M $1.16B -$77.9M $13.99 177
2024 Q2 88M $736M +$16.2M $8.22 171
2024 Q1 87.6M $675M +$15.6M $7.71 171
2023 Q4 85.6M $769M -$10.2M $8.99 162
2023 Q3 82.4M $736M -$62.5M $8.94 165
2023 Q2 82.6M $1.27B -$87.6M $15.36 163
2023 Q1 84.2M $1.89B +$265M $22.49 171
2022 Q4 72.7M $1.53B +$30.9M $21.03 151
2022 Q3 65.9M $1.62B -$1.53M $24.64 161
2022 Q2 68.9M $1.67B +$17.1M $24.23 162
2022 Q1 68.3M $1.76B +$101M $25.77 163
2021 Q4 60.6M $1.88B +$62.2M $31.04 161
2021 Q3 60.8M $1.47B +$7.96M $24.25 144
2021 Q2 60.5M $883M -$73.5M $14.59 129
2021 Q1 62.6M $1.56B +$255M $24.97 147
2020 Q4 52.2M $1.42B +$1.41B $27.26 133